Recent Updates
Recently added Catalysts
ENTA Positive Sentiment

EDP-978, a Potent KIT Inhibitor, Demonstrated Dose-Dependent Target-Engagement and a Favorable Pharmacokinetic Profile with Once-Daily Dosing Potential in Humans

Friday, February 27, 2026 BiopharmaWatch Research 2 min read
Add on Google
Key Takeaway: EDP-978, a potent KIT inhibitor, has demonstrated promising results in human trials. It exhibited dose-dependent target engagement and a favorable pharmacokinetic profile, suggesting the potential for once-daily dosing. This development could lead to effective treatments for conditions related to KIT inhibition.
Price reaction · baseline $14.41 (2026-02-26 close) · hit pre-market · 2 other ENTA headline(s) in the window, move may be shared
day 0 close
-0.8%

Market Sentiment Analysis

POSITIVE FACTORS

  • EDP-978 shows dose-dependent target engagement.
  • The pharmacokinetic profile is favorable for once-daily dosing.
  • Potential for effective treatment in KIT-related conditions.

BiopharmaWatch Analysis

From our catalyst data and publicly available data · not financial advice
Cash runway
~63 mo
Minimal dilution risk
Lead asset
EDP-235
Phase 2 · COVID-19

Full Press Release Details

• About About Us Management Team Board of Directors Timeline
• Pipeline Overview Hepatitis C Virus Respiratory Syncytial Virus SARS-CoV-2 Immunology KIT Inhibition STAT6 Inhibition MRGPRX2
• Science Overview Publications
• Patients Overview Clinical Trials Expanded Access Policy Resources
• Careers Join Us Culture Core Values Testimonials Benefits
• Collaborations Partnering
• Investors Overview Press Releases Events & Presentations Stock Information Stock Quote & Chart Historic Price Lookup Investment Calculator Analyst Coverage Financials Quartlery Results Annual Reports SEC Filings Corporate Responsibility Overview Environmental Social Governance Investor Resources Investor FAQs RSS Feed 2026 Annual Meeting Email Alerts
• Contact Us
• About Us
• Management Team
• Board of Directors
• Timeline
• Overview
• Hepatitis C Virus
• Respiratory Syncytial Virus
• SARS-CoV-2
• Immunology KIT Inhibition STAT6 Inhibition MRGPRX2
• KIT Inhibition
• STAT6 Inhibition
• MRGPRX2
• Overview
• Publications
• Overview
• Clinical Trials
• Expanded Access Policy
• Resources
• Join Us
• Culture
• Core Values
• Testimonials
• Benefits
• Partnering
• Overview
• Press Releases
• Events & Presentations
• Stock Information Stock Quote & Chart Historic Price Lookup Investment Calculator Analyst Coverage
• Financials Quartlery Results Annual Reports SEC Filings
• Corporate Responsibility Overview Environmental Social Governance
• Investor Resources Investor FAQs RSS Feed
• 2026 Annual Meeting
• Email Alerts
• Stock Quote & Chart
• Historic Price Lookup
• Investment Calculator
• Analyst Coverage
• Quartlery Results
• Annual Reports
• SEC Filings
• Overview
• Environmental
• Social
• Governance
• Investor FAQs
• RSS Feed
• Print Page Print Page
• Email Alerts Email Alerts
• RSS Feeds RSS Feeds
• Contact IR Contact IR

Frequently Asked Questions

What is EDP-978?

EDP-978 is a potent inhibitor targeting KIT, showing promise in clinical trials.

What are the benefits of EDP-978?

It demonstrated dose-dependent target engagement and a favorable pharmacokinetic profile.

How often can EDP-978 be dosed?

EDP-978 has potential for once-daily dosing based on its pharmacokinetic profile.

What conditions does EDP-978 target?

EDP-978 targets conditions related to KIT inhibition.

ShareAdd on Google
Tags: ENTA Viatris Investor Conferences Healthcare EDP-978 KIT inhibition pharmacokinetic profile once-daily dosing
Last updated: Feb 27, 2026

Biotech snapshot

Cash runway
$211M liquidity · $3M/mo burn
~63 mo
Minimal dilution risk
Lead asset
EDP-235Phase 2
COVID-19 →